1 min readLife Technologies Wins Verdict on its SOLiD Sequencing System
In this dispute, Illumina alleged that the SOLiD sequencing system commercialized by Applied Biosystems, a subsidiary of Life Technologies, infringed three patents, namely U.S. Patent Nos. 5,969,119; 5,750,341; and 6,306,597. The Court in this action previously ruled that the SOLiD system did not infringe two of the three patents and the jury was tasked with deciding whether Applied Biosystems’ SOLiD technology infringed U.S. Patent No. 5,969,119 (the ‘119 patent) and whether this patent was valid.
According to the announcement, after a seven day jury trial, the jury unanimously decided that the SOLiD sequencing technology did not infringe the ‘119 patent.
“We are very pleased with the decisions by the Court and the jury in this action,” said Kip Miller, President, Genetic Systems Division at Life Technologies. “The SOLiD sequencing platform was developed through substantial R&D efforts within Applied Biosystems. These decisions validate our belief that the SOLiD sequencing system is unique in its design and paves the way for us to continue building on its innovative design and superlative performance with the upcoming launch of SOLiD 3.0 this February.”